Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,654 across all filing types
Latest filing 2022-09-29 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关于股东股份质押变动的公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement from a company regarding changes in shareholder stock pledges. It details the number of shares pledged, pledge periods, pledgees, and the impact on company control and operations. There is no financial statement, earnings data, or management discussion. The document is a regulatory disclosure about share pledge changes by a controlling shareholder, which fits the category of Major Shareholding Notification or related shareholder pledge announcements. Given the content focuses on shareholder pledge changes and not on voting results or capital changes, the best fitting category is Major Shareholding Notification (MRQ). The document length is short and it is a direct announcement, not a report or certification. Therefore, the classification is MRQ with high confidence.
2022-09-29 Chinese
关于调整2021年限制性股票激励计划授予价格的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about adjusting the grant price of a 2021 restricted stock incentive plan. It details board and supervisory meetings, approvals, legal and financial advisor opinions, and the rationale for the price adjustment. The document is relatively short (3661 characters) and focuses on a specific corporate action related to stock incentives, not a full financial report or earnings release. It is not a full annual or interim report, nor a call transcript or governance report. It is a formal announcement of a corporate action related to stock incentives, which fits best under Regulatory Filings (RNS) as it does not match other more specific categories like Remuneration Information or Share Issue/Capital Change exactly. The document is not a report publication announcement since it contains substantive content about the adjustment and approvals, not just a notice of report availability.
2022-09-19 Chinese
浙江天册律师事务所关于贝达药业股份有限公司2021年限制性股票激励计划授予价格调整及预留部分授予相关事项的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the adjustment of the grant price and reserved portion grant related to the 2021 restricted stock incentive plan of Betta Pharmaceuticals Co., Ltd. It details approvals, authorizations, and compliance with relevant laws and regulations. The document is not a financial report, earnings release, or management discussion but a legal opinion on a specific corporate action related to stock incentives. It does not fit categories like Annual Report, Interim Report, or Capital/Financing Update. It is a regulatory filing related to corporate governance and compliance with securities laws. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (6491 characters) and content confirm it is not merely an announcement but a detailed legal opinion letter, yet it does not constitute a financial or management report itself.
2022-09-19 Chinese
监事会关于2021年限制性股票激励计划预留授予激励对象名单的核查意见
Regulatory Filings Classification · 95% confidence The document is a formal announcement from the supervisory board of a company regarding the verification opinion on the reserved grant list of the 2021 restricted stock incentive plan. It includes legal references, compliance checks, and confirmation of the eligibility of incentive recipients. The document is relatively short (1356 characters) and focuses on the approval and verification of a stock incentive plan rather than presenting financial data or detailed financial results. It does not contain financial statements or comprehensive financial analysis. It is not an annual report, interim report, earnings release, or any detailed financial report. Instead, it is a regulatory announcement related to corporate governance and compliance with stock incentive regulations. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-09-19 Chinese
独立董事关于第三届董事会第三十五次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on matters discussed at the 35th meeting of the third board of directors of Betta Pharmaceuticals Co., Ltd. It focuses on the adjustment of the 2021 restricted stock incentive plan's grant price and the granting of reserved restricted stocks. The content is related to corporate governance and compliance with regulatory rules regarding stock incentive plans. It does not contain financial statements or earnings data, nor is it a report or announcement of financial results. It is a governance-related document expressing independent directors' opinions on board matters, specifically about stock incentive plans and related approvals. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not a report publication announcement or regulatory filing. Hence, the classification is MANG with high confidence.
2022-09-19 Chinese
关于向激励对象授予预留限制性股票的公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement from a company regarding the granting of reserved restricted stock under a 2021 stock incentive plan. It includes specifics about the stock grant date, number of shares, grant price, eligibility, performance conditions, approval procedures, and legal and financial advisor opinions. The content focuses on the company's stock-based compensation plan and the allocation of shares to executives and employees. This type of document is related to management and board decisions about stock incentives and share grants to executives and key personnel. It is not a financial report, earnings release, or regulatory filing about financial results. It is also not a proxy statement or voting results announcement. The document is best classified as Board/Management Information (MANG) because it announces management-related decisions about stock incentives and executive compensation plans.
2022-09-19 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.